Formulation, Characterization, and Assessment of The Hepatoprotective and Toxicity Effects of Eudragit Nanoparticles Loaded with Silymarin
DOI:
https://doi.org/10.52783/jns.v14.3224Keywords:
Silymarin, hepatoprotective, Eudragit nanoparticles, nanoprecipitation, controlled drug release, liver toxicity, bioavailabilityAbstract
Silymarin, a flavonolignan complex extracted from Silybum marianum, is well known for its hepatoprotective activity. Due to its poor aqueous solubility and low bioavailability, its therapeutic application is limited. The aim of the present study was to design and develop Eudragit nanoparticles as a new drug delivery system to enhance the hepatoprotective activity of silymarin. The nanoparticles were prepared with the aid of the nanoprecipitation method and their drug release pattern, zeta potential, encapsulation efficiency, and size were all evaluated. Carbon tetrachloride (CCl₄)-induced hepatotoxicity model in Wistar rats was employed to evaluate hepatoprotective activity, and toxicity was evaluated by biochemical marker profiling and histopathological studies. The data suggested that the particle size of silymarin-loaded Eudragit nanoparticles was found to be 150–250 nm, the zeta potential was -35 mV, and the encapsulation efficiency was found to be 85%, resulting in sustained release for 48 hours. The hepatoprotection efficacy of the nanoparticles was significantly enhanced compared with that of free silymarin, as indicated by enhanced biochemical parameters (ALT, AST, ALP, and bilirubin) and maintained liver histology. In addition, the toxicity studies indicated that nanoparticles were nontoxic for therapeutic use. These results demonstrate that Eudragit nanoparticles are a promising approach to improving the hepatoprotection efficacy of silymarin while reducing toxicity and thus represent a potential drug candidate for the treatment of liver disease.
Downloads
Metrics
References
Abdullah, A. S., Sayed, I. E. T. E., El-Torgoman, A. M. A., Kalam, A., Wageh, S., & Kamel, M. A. (2022). Green synthesis of silymarin–chitosan nanoparticles as a new nano formulation with enhanced anti-fibrotic effects against liver fibrosis. International Journal of Molecular Sciences, 23(10), 5420.
Abou Assi, R., Abdulbaqi, I. M., & Siok Yee, C. (2021). The evaluation of drug delivery nanocarrier development and pharmacological briefing for metabolic-associated fatty liver disease (MAFLD): an update. Pharmaceuticals, 14(3), 215.
Das, S., Roy, P., Auddy, R. G., & Mukherjee, A. (2011). Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity. International journal of nanomedicine, 1291-1301.
Di Costanzo, A., & Angelico, R. (2019). Advanced nanotechnologies for enhancing the bioavailability of silymarin: a state of the art. Peer-reviewed version available at Molecules, 24, 2155.
Di Costanzo, A., & Angelico, R. (2019). Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules, 24(11), 2155.
El-Nahas, A. E., Allam, A. N., & El-Kamel, A. H. (2017). Mucoadhesive buccal tablets containing silymarin Eudragit-loaded nanoparticles: Formulation, characterisation and ex vivo permeation. Journal of microencapsulation, 34(5), 463-474.
El-Nahas, A. E., Allam, A. N., Abdelmonsif, D. A., & El-Kamel, A. H. (2017). Silymarin-loaded eudragit nanoparticles: formulation, characterization, and hepatoprotective and toxicity evaluation. Aaps Pharmscitech, 18, 3076-3086.
Madiyar, F., Suskavcevic, L., Daugherty, K., Weldon, A., Ghate, S., O’Brien, T., ... & Namilae, L. (2024). Optimizing Production, Characterization, and In Vitro Behavior of Silymarin–Eudragit Electrosprayed Fiber for Anti-Inflammatory Effects: A Chemical Study. Bioengineering, 11(9), 864.
Mishra, A. K., Neha, S. L., Rani, L., Jain, A., Dewangan, H. K., & Sahoo, P. K. (2023). Rationally designed nanoparticulate delivery approach for silymarin with natural bio-enhancer: In vitro characterization and in vivo evaluations of hepatoprotective effects in a mouse model. Journal of drug delivery science and technology, 86, 104580.
Mohsen, A. M., Asfour, M. H., & Salama, A. A. (2017). Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes. Drug development and industrial pharmacy, 43(12), 2043-2054.
Poltavets, Y. I., Kuznetsov, S. L., Tubasheva, I. A., Murav’eva, A. I., & Gukasova, N. V. (2021). Nano-and microsized forms of silymarin and silybin. Nanobiotechnology Reports, 16, 115-137.
Rohilla, S., & Bhatt, D. C. (2018). Significance of hepatoprotective liver specific targeted drug delivery: a review on novel herbal and formulation approaches in the management of hepatotoxicity. Current Drug Targets, 19(13), 1519-1549.
Salem, M. B., Mohammed, D. M., Hammam, O. A., & Elzallat, M. (2024). Mitigation of intrahepatic cholestasis induced by 17α-ethinylestradiol via nanoformulation of Silybum marianum L. BMC Complementary Medicine and Therapies, 24(1), 51.
Sherikar, A., Siddique, M. U. M., More, M., Goyal, S. N., Milivojevic, M., Alkahtani, S., ... & Nayak, A. K. (2021). Research Article Preparation and Evaluation of Silymarin-Loaded Solid Eutectic for Enhanced Anti-Inflammatory, Hepatoprotective Effect: In Vitro–In Vivo Prospect.
Tung, N. T., Tran, C. S., Nguyen, H. A., Nguyen, T. D., Chi, S. C., Pham, D. V., ... & Ho, X. H. (2019). Formulation and biopharmaceutical evaluation of supersaturatable self-nanoemulsifying drug delivery systems containing silymarin. International journal of pharmaceutics, 555, 63-76.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
